HER2 is a transmembrane receptor tyrosine kinase in the epidermal growth factor receptor family that is amplified or overexpressed in approximately 20% of breast cancers, and is associated with poor prognosis in the absence of systemic therapy (3). This evidence concerns the gene ERBB2 and breast cancer.